Cancer Management Guide
We will help to achieve for each individual the maximum possible level of certainty and efficiency in disease diagnosis, prognosis, and therapy selection. Our goal is to achieve the degree of accuracy of 90% or better for each client.
Flow chart of a decision-making process in clinical management of cancer patients on the basis of sequential sampling for monitoring of the stemness signature profiles in circulating tumor cells and primary tumor samples. Identification of the stemness gene expression profiles (Figs 1-4; JCO, 2008: 26: 2846-53) at any stage of this sequence would favor the diagnosis of therapy-resistant disease phenotype and trigger the requirement for application of the “next-in-line” aggressive treatment protocols and/or novel therapies specifically targeting master stemness pathways or relevant oncogenic state maintenance pathways. CTC, circulating tumor cell; FFPE, formalin-fixed paraffin embedded.
Reproduced from: Glinsky, GV. 2008. “Stemness” genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. Journal of Clinical Oncology, 26: 2846-53.
Issued US Patents